CVS settles with FTC, to count TrumpRx purchases toward insurance

• CVS must allow clients to opt out of rebate payment models, addressing criticism that these after-market discounts contribute to high drug costs
• The settlement requires CVS to count TrumpRx purchases toward health plan deductibles once regulations are in place, expanding the program's value for consumers
• TrumpRx.gov was launched in February 2026, offering discounted generic and branded drugs with focus on weight-loss medications from Eli Lilly and Novo Nordisk

CVS Settles with FTC on Drug Pricing and TrumpRx Integration

CVS Health's Caremark division has finalized a settlement with the Federal Trade Commission requiring significant changes to its pharmacy benefit management practices. The agreement mandates that CVS curb the use of after-market rebates and count consumer purchases made through TrumpRx.gov toward insurance deductibles once enabling regulations are implemented.

Key Settlement Terms:

• CVS must provide clients an option to opt out of rebate payment models
• Patient payments through TrumpRx will count toward health plan deductibles
• Similar to a previous settlement with Cigna's PBM division
• Expected to generate billions of dollars in drug price savings

TrumpRx Background:

President Trump launched TrumpRx.gov in February 2026, a website offering discounted generic and branded drugs, with particular emphasis on popular weight-loss medications from Eli Lilly and Novo Nordisk. The platform currently operates outside traditional insurance channels, directing cash-paying customers to drugmaker websites for discounts.

Market Implications:

The settlement addresses longstanding criticism that pharmacy benefit manager practices contribute to high drug costs. By requiring rebate transparency and integrating TrumpRx purchases with insurance deductibles, the agreement could significantly alter how Americans access and pay for prescription medications.

FTC Chairman Andrew Ferguson emphasized the Trump administration's commitment to combating anticompetitive behavior that inflates consumer drug prices. The settlement represents a major policy shift in pharmaceutical pricing and could pressure other PBMs to adopt similar practices, potentially disrupting the traditional rebate-based business model that has long characterized the industry.